Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.84 EPS, down 5.95% or $0.05 from last year’s $-0.79 per share.

At the moment 7 analysts are watching Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 3 rate it “Buy”, 2 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 3 analysts have a mean sales target of 0.00 million. For the quarter ending Jun-16, 3 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 6 analysts have a mean target of 0.04 million.

In terms of earnings per share, 3 analysts have a -0.82 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.86 EPS mean target and for the quarter ending Jun-16 there are 6 estimates of -3.32 EPS.

The biggest institutional shareholders in Karyopharm Therapeutics Inc. include Chione Ltd. which owns 9 million shares in the company valued at $245.34 million. Fidelity Management and Research Company is the second biggest holder with 5 million shares currently valued at 71.02 million whilst Franklin Advisers, Inc. has 5 million shares valued at 68.49 million.

Total shares held by institutions as of the most recent company filings are 38,461,056 with a reported 3,901,405 bought and 4,676,689 sold. These holdings make up 50.8% of the company’s outstanding shares.

Currently insiders hold 1,403,407 shares in the business which makes up 3.93% of shares. The biggest holder currently is Dr. Sharon Shacham, M.B.A.,PhD who owns 763,963 shares (2.14% of those outstanding), whilst Dr. Michael G. Kauffman,M.D.,PhD holds 562,596 (1.57% of shares outstanding) and Paul Brannelly holds 66,136 (0.19% of shares outstanding).

The stock increased 7.48% or $0.55 during the last trading session, hitting $12.02. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has fallen 25.29% over the past 6 months and is downtrending.